Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $60.73 million. The enterprise value is $127.62 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, before market open.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 22.01 million shares outstanding. The number of shares has increased by 30.96% in one year.
| Current Share Class | 22.01M |
| Shares Outstanding | 22.01M |
| Shares Change (YoY) | +30.96% |
| Shares Change (QoQ) | +1.91% |
| Owned by Insiders (%) | 15.33% |
| Owned by Institutions (%) | 11.37% |
| Float | 10.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.31 |
| Forward PS | n/a |
| PB Ratio | 2.18 |
| P/TBV Ratio | 5.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.26, with a Debt / Equity ratio of 2.42.
| Current Ratio | 0.26 |
| Quick Ratio | 0.21 |
| Debt / Equity | 2.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.31 |
Financial Efficiency
Return on equity (ROE) is -154.23% and return on invested capital (ROIC) is -20.27%.
| Return on Equity (ROE) | -154.23% |
| Return on Assets (ROA) | -14.63% |
| Return on Capital (ROIC) | -20.27% |
| Revenue Per Employee | $355,750 |
| Profits Per Employee | -$940,250 |
| Employee Count | 120 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 3.92 |
Taxes
In the past 12 months, Celularity has paid $10,000 in taxes.
| Income Tax | 10,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.83% in the last 52 weeks. The beta is 0.51, so Celularity's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | +34.83% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 3.34 |
| Relative Strength Index (RSI) | 52.28 |
| Average Volume (20 Days) | 3,168,651 |
Short Selling Information
The latest short interest is 743,723, so 3.38% of the outstanding shares have been sold short.
| Short Interest | 743,723 |
| Short Previous Month | 680,541 |
| Short % of Shares Out | 3.38% |
| Short % of Float | 6.79% |
| Short Ratio (days to cover) | 18.95 |
Income Statement
In the last 12 months, Celularity had revenue of $42.69 million and -$112.83 million in losses. Loss per share was -$5.55.
| Revenue | 42.69M |
| Gross Profit | 25.72M |
| Operating Income | -44.70M |
| Pretax Income | -196.29M |
| Net Income | -112.83M |
| EBITDA | -35.91M |
| EBIT | -44.70M |
| Loss Per Share | -$5.55 |
Full Income StatementBalance Sheet
The company has $467,000 in cash and $67.36 million in debt, giving a net cash position of -$66.89 million or -$3.04 per share.
| Cash & Cash Equivalents | 467,000 |
| Total Debt | 67.36M |
| Net Cash | -66.89M |
| Net Cash Per Share | -$3.04 |
| Equity (Book Value) | 27.81M |
| Book Value Per Share | 1.27 |
| Working Capital | -50.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.51 million and capital expenditures -$878,000, giving a free cash flow of -$21.39 million.
| Operating Cash Flow | -20.51M |
| Capital Expenditures | -878,000 |
| Free Cash Flow | -21.39M |
| FCF Per Share | -$0.97 |
Full Cash Flow StatementMargins
Gross margin is 60.24%, with operating and profit margins of -104.70% and -264.30%.
| Gross Margin | 60.24% |
| Operating Margin | -104.70% |
| Pretax Margin | -264.28% |
| Profit Margin | -264.30% |
| EBITDA Margin | -84.11% |
| EBIT Margin | -104.70% |
| FCF Margin | -174.49% |